Background
==========

Coronary heart disease (CHD), also known as coronary artery disease (CAD), is a form of atherosclerosis-related cardiovascular disease with a global mortality rate of over 7 million deaths \[[@b1-medscimonit-22-31]\]. The disease progresses as plaques build up along the inner walls of heart arteries, narrowing the lumen of arteries and reducing blood flow to the heart. CHD usually occurs in middle-aged and elderly individuals and males are more vulnerable than females \[[@b2-medscimonit-22-31]\]. In light of the unfavorable consequences of CHD, the etiology of CHD has been extensively investigated. It was demonstrated that the cumulative effects of environmental and genetic factors could boost the incidence of the disease \[[@b3-medscimonit-22-31]\]. Furthermore, several case-control studies have suggested certain candidate genes that could be linked with CHD, and the heritability of CHD is estimated to be 50--60%. The genes have been demonstrated to be involved in inflammation, lipid metabolism, coagulation, and regulation of vascular tone, many of which have been deemed to be associated with various atherosclerosis-related phenotypes \[[@b4-medscimonit-22-31]\]. Previous studies have confirmed the association of raised level of serum and plasma VEGF with atherosclerosis \[[@b5-medscimonit-22-31]\] and CHD, respectively \[[@b6-medscimonit-22-31]\]. Polymorphisms of *KDR* have also been suggested to be related with risk of CHD via the role of *KDR* in the formation of blood vessel networks and atherosclerosis \[[@b7-medscimonit-22-31]--[@b9-medscimonit-22-31]\].

*VEGF*, typically expressed as a 46-kDa homodimer located on chromosome 6, can encode a mitogen that promotes vascular endothelial cell proliferation and angiogenesis \[[@b10-medscimonit-22-31]\], and the abnormal angiogenesis within blood vessels has been reported to be implicated in atherosclerosis and arterial diseases \[[@b11-medscimonit-22-31], [@b12-medscimonit-22-31]\]. Furthermore, *VEGF* are considered to be correlated with various signaling receptor complexes -- *VEGF* binding receptors *VEGFR-1*(*flt-1*), *VEGFR-2* (*KDR/flk-1*), and *VEGFR-3* (also known as *FLT-4*) -- while there also exist *VEGF165* isoform-specific receptors, neurophilin-1 and neurophilin-2 \[[@b13-medscimonit-22-31]--[@b15-medscimonit-22-31]\]. As a receptor of *VEGF*, *KDR* is expressed in manifold cells, such as endothelial progenitor cells (EPCs), endothelial cells, and hematopoietic cells \[[@b9-medscimonit-22-31]\]. Additionally, *KDR* is regarded as a crucial receptor mediating angiogenesis and it seems to be essential to survival and integrity of endothelial cells \[[@b16-medscimonit-22-31],[@b17-medscimonit-22-31]\].

Considering the potentially critical roles of *VEGF* and *KDR* in the pathogenesis of CHD, it is hypothesized that single-nucleotide polymorphisms (SNPs) located in the functional regions of *VEGF* and *KDR* might also facilitate CHD by influencing the expression of *VEGF* and *KDR*. Thus, the present case-control study was performed to explore the association of tagging SNPs (tag-SNPs) in *VEGF* (rs699947, rs2010963, and rs3025010) and *KDR* (rs2071559, rs2305948, and rs1870377) with risk of CHD in a Chinese Han population. We also investigated the synergic effects of SNPs combined in evolution of CHD

Material and Methods
====================

Ethics statement
----------------

The current study was conducted in strict accordance with the protocol approved by the Ethics Committee of the Second Hospital of Dalian Medical University (Dalian, China). All participants were recruited by the Second Hospital of Dalian Medical University and they all (or their guardians) signed informed consents. Moreover, this research followed the tenets of the Declaration of Helsinki.

Study population
----------------

A total of 1066 specimens were obtained from the Second Hospital of Dalian Medical University from June 2011 to May 2014. In all, 533 unrelated CHD patients (250 males and 283 females) and 533 unrelated healthy volunteers (255 males and 278 females) were included in the present study, as outlined in [Table 1](#t1-medscimonit-22-31){ref-type="table"}. All enrolled subjects were of Chinese Han ethnicity.

Inclusion criteria were: (1) all the participants in the case group were diagnosed with CHD by coronary arteriography (CAG); (2) the coronary angiography reveals more than 50% narrowing of the lumen of at least 1 of the major coronary arteries; and (3) all subjects were at least 18 years old and they were fully informed about the research. Exclusion criteria were: (1) the participants were subject to chest pain due to other disorders, such as other cardiac disorders, severe neurosis, menopausal syndrome, cervical spondylosis, hyperthyroidism, and colopathy; (2) the subjects had severe dysfunctions of the liver, kidney, or lung, and hematopiesis; (3) their major coronary artery had no more than 20% stenosis; (4) participants were either under 18 years old or at the stage of pregnancy/lactation; (5) subjects had life-threatening diseases such as tumors and acquired immune deficiency syndrome (AIDS); and (6) the information of eligible subjects did not match the inclusion criterion or they were incomplete. Individuals who had a history of myocardial infarction (MI) or other vascular diseases and those who had undergone heart surgery were also excluded.

Risk factors of CHD
-------------------

A complete series of clinical characteristics of CHD patients and healthy controls are shown in [Table 1](#t1-medscimonit-22-31){ref-type="table"}, including mean age and sex ratio of the participants. Among the mentioned features, certain vascular risk factors should be noted, such as body mass index (BMI), smoking status, alcohol consumption, hypertension, and diabetes status. The smoking status was defined as the consumption of at least 5 cigarettes per day or having a history of smoking in the last year. Diabetes was diagnosed when the subject had a fasting glucose above 7.8 mmol/l, or more than 11.1 mmol/l at 2 h after oral glucose challenge. Arterial hypertension was defined as the mean of 3 independent blood pressures as systolic pressure no less than 140 mmHg or diastolic pressure no less than 90 mmHg or the use of antihypertensive drugs. The alcohol consumption was defined as no less than 2 ounces of liquor per day or 4 ounce of beer per day. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were obtained using a sphygmomanometer of the same type. The difference of SBP and DBP equals the pulse pressure.

SNP selection
-------------

In the present study, the SNPs were obtained from an unrelated Chinese population in Shanghai with the public database (HapMap). Tag-SNPs were identified with use of the pair-wise option of Haploview 4.2 software and an r^2^ of 0.8 was used as a threshold for the analysis ([Figure 1](#f1-medscimonit-22-31){ref-type="fig"}) \[[@b18-medscimonit-22-31]\]. Finally, 3 SNPs in *VEGF* (rs699947, rs2010963, and rs3025010) and 3 SNPs in *KDR* (rs2071559, rs2305948, and rs1870377) were selected. The relative SNP positions in *KDR* and *VEGF* are shown in [Figures 2](#f2-medscimonit-22-31){ref-type="fig"} and [3](#f3-medscimonit-22-31){ref-type="fig"}, respectively.

Genetic analysis
----------------

A 5-ml venous blood sample was collected from each participant into a sterile tube containing heparin sodium. The mixtures of blood and heparin sodium were subsequently centrifuged at 3000 rpm for 10 min at room temperature, after which the separated plasma samples were stored at −20°C. Genomic DNA was extracted from frozen peripheral blood samples via a QIAmp Blood Mini Kit (Qiagen Inc., Valencia, California, United States) using the manufacturer's protocols \[[@b19-medscimonit-22-31]\]. Tag SNPs were then amplified with the 9700 PCR System (Applied Biosystems) on the basis of the primers designed by Primer3 software ([Table 2](#t2-medscimonit-22-31){ref-type="table"}), after which the PCR products were purified by Shrimp Alkaline Phosphatase (SAP) method \[[@b18-medscimonit-22-31]\]. Finally, the SNaPshot assay (Applied Biosystems) was performed to confirm genotypes of 6 DNA samples. All genotyping procedures were carried out in a double-blind manner and the whole assays were proved to be reliable.

Statistical analysis
--------------------

Data are presented as mean ± standard deviation (SD) or number (percentage). The chi-square test and Student's t-test were used to compare case and control groups, as appropriate. The goodness-of-fit chi-square test was employed to assess Hardy-Weinberg equilibrium (HWE) for each tag-SNP. Four genetic models -- the allelic (1/2 *vs.* 1/1), dominant (1/2+2/2 *vs.* 1/1), homozygous (2/2 *vs.* 1/1), and recessive (2/2 *vs.* 1/1+1/2) models -- were used to assess the association of *VEGF* and *KDR* genetic polymorphisms with CHD susceptibility with odds ratios (ORs) and their 95% confidence intervals (CIs). Multivariate logistic regression was also used to estimate the association of the 6 tag-SNPs with risk of CHD after adjustment of age, sex, BMI, smoking status, hypertension, diabetes, and drinking status. All statistical analyses were conducted with STATA Version 12.0 software (Stata Corp, College Station, TX) and a 2-sided P value less than 0.05 was considered to be statistically significant.

Results
=======

The samples included in the present study were obtained from 533 CHD subjects and 533 healthy controls with aid of the Second Hospital of Dalian Medical University (Dalian, China). Genotype frequencies in both groups conformed to Hardy-Weinberg equilibrium (HWE) ([Table 2](#t2-medscimonit-22-31){ref-type="table"}). The selected characteristics of cases and controls are shown in [Table 1](#t1-medscimonit-22-31){ref-type="table"}. Specifically, no statistically significant difference was observed for age (*P*=0.954), sex (*P=*0.759), BMI (*P=*0.709), SBP (*P=*0.912), DBP (*P=*0.872), pulse pressure (*P=*0.892), or smoking status (*P=*0.157). Nonetheless, several clinical characteristics, including hypertension, diabetes status, and alcohol consumption, displayed statistically remarkable distinctions between CHD patients and healthy controls (*P*\<0.001).

Associations between VEGF gene polymorphisms and the risk of CHD
----------------------------------------------------------------

As shown in [Table 3](#t3-medscimonit-22-31){ref-type="table"}, there existed no significant distinctions in genotype and allele distribution of rs3025010 (T\>C) between CHD patients and controls. Furthermore, rs2010963 (C\>G) was simply linked with risk of CHD before influences of clinical characteristics (e.g., BMI, smoking, alcohol consumption, diabetes, and hypertension) were considered. Subjects carrying variant genotypes (CG/GG) had a decreased CHD risk when compared with wild genotype CC (OR=0.78, 95%CI=0.62--0.99, *P*=0.049). However, rs699947 (T\>C) in the 5′UTR of *VEGF* was significantly associated with CHD risk when confounding factors investigated in this study were all allowed for. Compared with individuals with homozygote TT genotype, for instance, subjects carrying the variant genotypes (TC/CC) had a notably increased CHD risk (OR=1.33, 95%CI=1.01--1.76, *P*=0.044).

Associations between KDR gene polymorphisms and the risk of CHD
---------------------------------------------------------------

It was obvious that all the 3 tag-SNPs were associated with CHD risk ([Table 3](#t3-medscimonit-22-31){ref-type="table"}) before multivariate-based logistic regression was applied. Regarding rs2071559 (T\>C) in the 5′ near gene of *KDR*, the subjects carrying the variant genotypes (TC/CC) had a signally increased CHD risk compared to carriers of TT (OR=1.38, 95%CI=1.04--1.83, *P=*0.026) before multivariate-based regression analysis. Nonetheless, 2 additional tag-SNPs -- rs2305948 and rs1870377, located in the Exon 7 and Exon 11 of *KDR* respectively -- were both associated with CHD risk even after exclusion of interferences, because the subjects carrying the variant genotypes AA/GA and TT separately had an higher CHD risk than the corresponding carriers of GG (OR=3.04, 95%CI=1.29--7.17, *P=*0.011) and AA/AT (OR=2.83, 95%CI=1.47--5.46, *P*=0.002).

Association between haplotypes of 5 SNPs involved and susceptibility to CHD
---------------------------------------------------------------------------

Among the 14 haplotypes ultimately studied after removing ones with frequency lower than 0.03, we observed that carriers of C-C-C-G-T, T-C-T-G-T, T-G-T-G-A, and T-G-T-G-T were less prone to CHD than carriers with other haplotypes (OR=0.42, 95% CI: 0.22--0.78; OR=0.65, 95% CI: 0.50--0.85; OR=0.52, 95% CI: 0.32--0.87; OR=0.59, 95% CI: 0.41--0.85, respectively). In contrast, haplotypes C-C-T-G-T and T-G-T-G-T were closely associated with incremental risk of CHD in comparison with other haplotypes (OR=7.02, 95% CI: 3.19--15.47; OR=2.99, 95% CI: 1.54--5.84, respectively).

Discussion
==========

In the current case-control study, we found a significant association of 5 polymorphisms on *VEGF* and *KDR* with susceptibility to CHD in a Chinese Han population. In particular, mutants of the 3 SNPs (rs699947, rs2305948 and rs1870377) were still risk factors for CHD development after the effects of certain clinical characteristics (e.g., BMI, smoking, alcohol consumption, diabetes, and hypertension) were eliminated. Simultaneously, haplotype analyses revealed that integration of 5 SNPs would either raise or reduce risk of CHD.

VEGF, the renowned series of glycoprotein, is largely composed of secretory materials of the vascular endothelial cells, as well as additional cellular types \[[@b20-medscimonit-22-31],[@b21-medscimonit-22-31]\]. The appropriate binding of VEGF and its matching KDR, uniquely expressed and present in the endothelial cells, could primarily contribute to mediating neovascularization of atherosclerosis plaques by supplementing nutrition for the plaques and thus enlarging them \[[@b22-medscimonit-22-31],[@b23-medscimonit-22-31]\]. The VEGF/KDR axis, furthermore, could also account for the occurrence of inflammatory responses in relation to vessel walls through inducing the generation of relevant cytokines (e.g., IL-6, IL-8, and GRO-α), roles of which have been demonstrated to be of significance in 3 interconnected pathophysiological durations involved with evolution of CHD: formation of atherosclerosis, rupture of plaques, and coronary spasm \[[@b24-medscimonit-22-31]--[@b27-medscimonit-22-31]\]. It still remains debated, nonetheless, whether VEGF serves as a pro-atherosclerosis factor because VEGF has been conceived as a cause of stepped-up re-endothelialization, thereby resisting intimal thickening and thrombus development \[[@b28-medscimonit-22-31],[@b29-medscimonit-22-31]\]. The controversy could be construed as distinct phenomena resulting from relatively higher or lower ratio of various isoforms of VEGF. Double isoforms of VEGF165, VEGF 165a, and VEGF 165b possess pro-angiogenic and anti-angiogenic properties, and higher ratios of a/b or b/a would either promote or inhibit the evolution of atherosclerosis, with regulation controlled by insulin-like growth factor (IGF) \[[@b30-medscimonit-22-31]\]. The roles of polymorphisms mentioned in the current study obviously tended to facilitate the progression of atherosclerosis with consequently high a-to-b ratios of VEGF isoforms. Because type II diabetes (T2D) is thought to advance the development of atherosclerosis and the accompanying cardiac complications \[[@b31-medscimonit-22-31],[@b32-medscimonit-22-31]\], the genetic mutants making predisposition to T2D and myocardial infarctions possible could also be potentially associated with the occurrence of CHD, such as polymorphisms of rs699947, rs201096, rs3025010, rs2071559, rs2305948, and rs1870377 \[PMID: 17264508; PMID: 25128838\].

Of the 3 eligible SNPs in *VEGF*, rs3025010 is situated in the intron area, is cleaved after being transcribed into mRNAs and hence does not usually strongly affect protein functions. In contrast, rs699947 and rs2010963 are located in the 5′UTR region, affecting the transcription and expression of *VEGF*. The dissimilarity can, to a certain extent, account for the differentiations in associations between SNPs and susceptibility to CHD. More specifically, rs2010963 (94C\>G) is probably a functional polymorphism, because serum VEGF levels in subjects with CC genotype have been demonstrated to be remarkably higher than in other genotypes \[[@b33-medscimonit-22-31]--[@b35-medscimonit-22-31]\]. Additionally, the 3 SNPs of *KDR*, located in the 5′ near gene and exon regions, could affect differential expression of *KDR* and thus affect risk of CHD through interfering with the efficiency of *VEGF* binding. According to Shahbazi et al., the wild-type allele *VEGF* 2055CC is correlated with elevated *VEGF* concentration, seemingly conferring protection against CHD \[[@b36-medscimonit-22-31],[@b37-medscimonit-22-31]\]. Howell et al. also verified that *VEGF* 2055AA genotype could be considered as a risk factor for atherosclerosis, which is consistent with the regulation of *VEGF* in the endothelial integrity of coronary artery walls \[[@b38-medscimonit-22-31]\]. All the above results are in line with the fact that CHD is closely related with the expression level of *VEGF* and the binding efficiency of *KDR*, indicating the crucial roles of SNPs on *KDR* and *VEGF* in CHD pathogenesis ([Table 3](#t3-medscimonit-22-31){ref-type="table"}).

However, as CHD development was primarily attributed to the complicated interplay of genetic and environmental factors, there might sometimes appear illusions that certain polymorphisms elevate risk of CHD, but in fact it was concomitant disorders or unhealthy lifestyles of subjects that were really correlated with risk of CHD. Specifically, among the 5 SNPs (rs699947, rs2010963, rs2071559, rs2305948, and rs1870377) previously regarded as the underlying etiology of CHD development, mutants of VEGF (rs699947) and KDR (rs2305948 and rs1870377) could predispose to CHD after excluding the effects of other factors (BMI, SBP, pulse, DBP, smoking, alcohol consumption, hypertension, and diabetes) via analysis of multivariate logistic regression ([Table 3](#t3-medscimonit-22-31){ref-type="table"}).

As for the synergic reactions of all 5 SNPs involved, it is interesting to discover that carriers of 4 haplotypes (C-C-C-G-T, T-C-T-G-A, T-C-T-G-T, and T-G-T-G-A) seem to be less susceptible to CHD, while carriers of other haplotypes (C-C-T-G-T and T-G-T-G-T) tended to suffer from CHD more readily. In fact, the protective role of T allele of rs699947 and G allele of rs2305948 were highlighted in terms of haplotype T-C-T-G-A and T-C-T-G-T when compared with T/A alleles of rs1870377 ([Table 4](#t4-medscimonit-22-31){ref-type="table"}). Moreover, the significance of rs1870377 was pronounced when considering haplotypes T-G-T-G-A and T-G-T-G-T, since the mutant T allele of rs1870377 enables carriers of T-G-T-G-T to be less vulnerable to CHD, while the A allele appears to play the opposite role. It could be supposed from the 4 haplotypes mentioned above that the function of rs1870377 (A\>T) would overwhelm that of mixed effects of rs699947 (T\>C) and rs2305948 (G\>A) in the presence of T-G-T-G composed of another 4 SNPs, yet the relationship was reversed with haplotype T-C-T-G. Finally, the positive effect of rs2305948 was relatively outstanding in haplotype C-C-C-G-T for CHD development, while combined actions of rs699947 and rs1870377 in view of C-C-T-G-T. Admittedly, the conclusion mentioned above might not be applicable to other groups, as investigations would differ according to ethnic background of subjects and sample size. A possibility of selection bias also could not be ruled out, in that our case-control study was hospital-based.

Conclusions
===========

In conclusion, genetic polymorphisms on *VEGF* (rs699947) and KDR (rs2305948and rs1870377), as well as relevant haplotypes, may serve as genetic markers that might be useful in future investigations on the pathogenesis of CHD.

Further investigations are, therefore, required to validate the functional relationship between SNPs of *VEGF* and *KDR* and susceptibility to CHD in terms of ethnic differences, which might contribute to the development of novel methods for diagnosis and treatment of CHD in the future.
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###### 

Comparison of coronary heart disease patients and controls by selective characteristics.

  Clinical characteristics   CHD patients (n=533)   Healthy controls (n=533)   *P*-value                                                      Adjusted *P*-value
  -------------------------- ---------------------- -------------------------- -------------------------------------------------------------- ----------------------------------------------------------
  Age (mean ±SD)             62.3±10.2              61.5±9.3                   0.181[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}         0.212[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}
  Male/female                250/283                255/278                    0.759[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}         0.804[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}
  BMI (kg/m^2^)              24.03±3.33             22.41±2.77                 \<0.001[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}       \<0.001[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}
  SBP (mmHg)                 131.12±22.51           129.71±21.12               0.187[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}         0.259[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}
  DBP (mmHg)                 78.98±14.31            80.11±13.21                0.182[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}         0.180[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}
  Pulse pressure (mmHg)      51.33±16.41            50.12±14.88                0.208[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}         0.207[b](#tfn3-medscimonit-22-31){ref-type="table-fn"}
  Smoking                                                                                                                                     
   Yes                       256                    233                        0.157[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}         0.141[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}
   No                        277                    300                                                                                       
  Alcohol consumption                                                                                                                         
   Yes                       242                    144                        **\<0.001**[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}   \<0.001[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}
   No                        291                    389                                                                                       
  Hypertension                                                                                                                                
   Yes                       387                    223                        **\<0.001**[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}   \<0.001[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}
   No                        146                    310                                                                                       
  Diabetes                                                                                                                                    
   Yes                       149                    69                         **\<0.001**[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}   \<0.001[a](#tfn2-medscimonit-22-31){ref-type="table-fn"}
   No                        384                    464                                                                                       

CHD -- coronary heart disease;

p value of student's t test;

chi-square test; Adjusted *P-*value: significance after adjustment by multivariate-based logistic regression analysis.

###### 

Primers of *VEGF and KDR* genetic polymorphisms for PCR amplification.

  -------------------------------------------------------------------------------------------------------------
  SNP              Gen Pos        Alias name           Primers for PCR amplification       HWE     Global MAF
  ---------------- -------------- -------------------- ----------------------------------- ------- ------------
  ***VEGF***                                                                                       

   **rs699947**    5′UTR          2055A\>C(−2578)      F: 5′-GCTGTAGGCCAGACCCTG-3′\        0.280   0.325
                                                       R: 3′-ACCCACCTATTAGTCTGAC-5′                

   rs201096        5′UTR          94C\>G(−634)         F: 5′-TGATATTCATTGATCCGGGTTT -3′\   0.583   0.008
                                                       R: 3′-CTGTCCCCGTTTCACTCA-5′                 

   rs3025010       Intron 5       14625T\>C            F: 5′-CCTCCTTTCTTCCCTGTG -3′\       0.009   0.352
                                                       R: 3′-AACTTCCCCTGTCCGATG-5′                 

  ***KDR***                                                                                        

   rs2071559       5′ near gene   −906T\>C(−604T\>C)   F: 5′-TTGGGAAATAGCGGGAAT-3′\        0.705   0.499
                                                       R: 3′-GACCCGTTCACGCAAAAG-5′                 

   **rs2305948**   Exon 7         889G\>A(1192)        F: 5′-ACCCAAGTTCCTGACTACAA-3′\      0.088   0.153
                                                       R: 3′-TTAGACCCGAAACCATTT-5′                 

   rs1870377       Exon 11        1416A\>T(1719)       F: 5′-CCATTCTTCACAAGGGTA -3′\       0.051   0.212
                                                       R: 3′-CCTTTGAATCTTCGGTGA-5′                 
  -------------------------------------------------------------------------------------------------------------

###### 

Associations of three common polymorphisms of *VEGF* and *KDR* with risk of coronary heart disease.

  SNP/genotype                       CHD patients (n=533)   Healthy controls (n=533)   OR (95% CI)         χ^2^    P value     Adjusted OR (95% CI)    Adjusted *P* value
  ---------------------------------- ---------------------- -------------------------- ------------------- ------- ----------- ----------------------- --------------------
  **rs699947 (T\>C)**                                                                                                                                  
  TT                                 180                    217                        Ref.                                                            
  TC                                 250                    237                        1.28 (0.98--1.68)   3.357   0.067       2.05 (1.49, 2.82)       **\<0.001**
  CC                                 103                    79                         1.68 (1.18--2.24)   6.325   **0.012**   2.45 (1.62, 3.70)       **\<0.001**
  Dominant (CC+TC *vs.* TT)                                                            1.35 (1.05--1.73)   5.495   **0.019**   1.33 (1.01, 1.76)       **0.044**
  Recessive (CC *vs.* TT+TC)                                                           1.38 (0.99--1.90    3.816   0.051       1.56 (1.09, 2.24)       **0.015**
  Allele (C allele *vs.* T allele)                                                     1.27 (1.07--1.51)   7.277   **0.007**   ----                    ----
  **rs2010963 (C\>G)**                                                                                                                                 
  CC                                 250                    223                        Ref.                                                            
  CG                                 233                    239                        0.85 (0.66--1.10)   1.508   0.219       0.78 (0.58, 1.05)       0.100
  GG                                 50                     71                         0.55 (0.37--0.84)   7.910   **0.005**   0.76 (0.48, 1.19)       0.229
  Dominant (CG+GG *vs.* CC)                                                            0.78 (0.62--0.99)   3.884   **0.049**   0.780 (0.595, 1.023)    0.073
  Recessive (GG *vs.* CC+CG)                                                           0.60 (0.40--0.89)   6.539   **0.011**   0.83 (0.54, 1.27)       0.378
  Allele (G allele *vs.* C allele)                                                     0.78 (0.65--0.94)   7.134   **0.008**   ----                    ----
  **rs3025010 (T\>C)**                                                                                                                                 
  TT                                 142                    160                        Ref.                                                            
  TC                                 287                    290                        1.12 (0.84--1.47)   0.587   0.444       ----                    ----
  CC                                 104                    94                         1.25 (0.87--1.79)   1.450   0.229       ----                    ----
  Dominant (CC+TC *vs.* TT)                                                            1.15 (0.88--1.50)   1.024   0.312       ----                    ----
  Recessive (CC *vs.* TT+TC)                                                           1.16 (0.85--1.58)   0.895   0.344       ----                    ----
  Allele (C allele *vs.* T allele)                                                     1.11 (0.93--1.31)   1.360   0.244       ----                    ----
  **rs2071559 (T\>C)**                                                                                                                                 
  TT                                 122                    143                        Ref.                                                            
  TC                                 253                    261                        1.29 (0.95--1.74)   0.700   0.100       1.25 (0.89, 1.76)       0.192
  CC                                 158                    129                        1.47 (1.04--2.06)   4.804   **0.028**   1.36 (0.93, 1.99)       0.117
  Dominant (CC+TC *vs.* TT)                                                            1.38 (1.04--1.83)   4.954   **0.026**   1.24 (0.91, 1.70)       0.169
  Recessive (CC *vs.* TT+TC)                                                           1.24 (0.94--1.63)   2.288   0.130       1.16 (0.85, 1.57)       0.347
  Allele (C allele *vs.* T allele)                                                     1.21 (1.02--1.43)   4.777   **0.029**   ----                    ----
  **rs2305948 (G\>A)**                                                                                                                                 
  GG                                 388                    416                        Ref.                                                            
  GA                                 122                    105                        1.25 (0.93--1.67)   2.131   0.144       1.25 (0.90, 1.76)       0.189
  AA                                 23                     12                         2.06 (1.01--4.19)   4.089   **0.043**   **3.04 (1.29, 7.17)**   **0.011**
  Dominant (AA+GA *vs.* GG)                                                            1.33 (1.00--1.76)   3.967   **0.046**   **1.39 (1.02, 1.91)**   **0.040**
  Recessive (AA *vs.* GA+GG)                                                           1.96 (0.96--3.98)   5.575   0.059       **2.54 (1.13, 5.75)**   **0.025**
  Allele (G allele *vs.* A allele)                                                     1.36 (1.06--1.74)   5.950   **0.015**   ----                    ----
  **rs1870377 (A\>T)**                                                                                                                                 
  AA                                 311                    325                        Ref.                                                            
  AT                                 183                    192                        1.23 (0.96--1.59)   0.063   0.802       0.99 (0.74, 1.32)       0.938
  TT                                 39                     16                         2.00 (1.05--3.84)   4.525   **0.033**   **2.66 (1.35, 5.24)**   **0.005**
  Dominant (TT+AT *vs.* AA)                                                            1.29 (1.01--1.65)   4.196   **0.041**   1.15 (0.88, 1.52)       0.311
  Recessive (TT *vs.* AA+AT)                                                           1.84 (0.97--3.51)   3.569   0.059       2.83 (1.47, 5.46)       0.002
  Allele (T allele *vs.* A allele)                                                     1.27 (1.04--1.56)   5.374   **0.020**   ----                    ----

CHD -- coronary heart disease; OR -- odds ratio; CI -- confidence interval; Adjusted OR -- odds ratio after adjustment by multivariate-based logistic regression analysis; Adjusted *P-*value -- significance after adjustment by multivariate-based logistic regression analysis.

###### 

Haplotype analysis for three polymorphisms of *VEGF* (rs699947 and rs201096) and *KDR* (rs2071559, rs2305948 and rs1870377).

  Haplotpe        Case              Control           χ^2^         *P* (Fisher)   *P* (Pearson)   OR (95% CI)
  --------------- ----------------- ----------------- ------------ -------------- --------------- ------------------------
  C-C-C-G-A       94 (0.088)        80 (0.075)        1.283        0.257          0.257           1.20 (0.88, 1.64)
  **C-C-C-G-T**   **14 (0.013)**    **33 (0.031)**    **7.828**    **0.005**      **0.005**       **0.42 (0.22, 0.78)**
  C-C-T-G-A       118 (0.111)       101 (0.095)       1.727        0.189          0.189           1.21 (0.91, 1.61)
  **C-C-T-G-T**   **48 (0.045)**    **7 (0.007)**     **31.239**   **\<0.001**    **\<0.001**     **7.02 (3.19, 15.47)**
  C-G-C-G-A       43 (0.041)        44 (0.042)        0.002        0.968          0.968           0.99 (0.65, 1.52)
  C-G-T-G-A       41 (0.039)        45 (0.042)        0.145        0.703          0.703           0.92 (0.60, 1.42)
  T-C-C-A-A       33 (0.032)        24 (0.023)        1.799        0.180          0.180           1.44 (0.84, 2.45)
  T-C-C-G-A       150 (0.141)       141 (0.132)       0.497        0.481          0.481           1.10 (0.85, 1.41)
  T-C-C-G-T       56 (0.053)        38 (0.036)        3.853        0.050          0.050           1.52 (0.99, 2.32)
  **T-C-T-G-A**   **107 (0.100)**   **157 (0.147)**   **10.378**   **0.001**      **0.001**       **0.65 (0.50, 0.85)**
  **T-C-T-G-T**   **24 (0.022)**    **45 (0.042)**    **6.473**    **0.011**      **0.011**       **0.52 (0.32, 0.87)**
  T-G-C-G-A       76 (0.071)        89 (0.084)        1.020        0.313          0.313           0.85 (0.62, 1.17)
  **T-G-T-G-A**   **49 (0.046)**    **81 (0.076)**    **8.057**    **0.005**      **0.005**       **0.59 (0.41, 0.85)**
  **T-G-T-G-T**   **34 (0.032)**    **12 (0.011)**    **11.356**   **0.001**      **0.001**       **2.99 (1.54, 5.84)**

OR -- odds ratio; CI -- confidence interval.
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